|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Qiagen N V's Business Segments
Qiagen N.V. is a prominent global biotech company that focuses on providing specialized sample and assay technologies for various sectors within the life sciences. Its offerings are crucial in molecular diagnostics, applied testing, academic and pharmaceutical research, genomic analysis, and personalized healthcare. The company operates across several segments, each catering to distinct applications and audiences.
Segments
1. Life Sciences:
This segment encompasses a wide array of products and solutions tailored for genomic research. Key offerings include:
- Gene Expression Analysis: Tools and reagents for measuring gene expression levels in various biological samples.
- Next-Generation Sequencing (NGS): Comprehensive workflows and reagents for NGS, facilitating large-scale genomic studies with high accuracy.
- Mutation Detection: Technologies designed to identify genetic mutations and variations, which are pivotal in cancer research and genetic disorders.
- High-Throughput PCR and qPCR Systems: Automated platforms for performing quantitative PCR, enabling researchers to conduct multiple assays simultaneously.
- Bioinformatics Software: Solutions for managing and analyzing large datasets generated from genomic research, including tools for variant interpretation and molecular data analysis.
- Sample Preparation Kits: Dedicated kits for the extraction and purification of DNA and RNA from various sample types.
2. Molecular Diagnostics:
This segment is essential for healthcare and clinical settings, focusing on the rapid and precise detection of diseases:
- Infectious Disease Detection: Assays and testing kits designed to identify viral, bacterial, and parasitic infections quickly, contributing to timely diagnosis and treatment.
- Oncology Testing: A variety of solutions that enable the detection of cancer-related biomarkers, supporting personalized treatment plans.
- Genetic Disorder Testing: Tools for detecting hereditary conditions, ensuring early diagnosis and intervention strategies.
- Automated Laboratory Systems: Integrated solutions for clinical labs, aimed at streamlining workflows and improving accuracy in diagnostic testing.
3. Applied Testing:
This segment focuses on testing solutions tailored for environmental safety, food industry, forensic analysis, and veterinary diagnostics:
- Environmental Monitoring: Tools and assays for detecting contaminants in air, soil, and water, addressing public health and safety concerns.
- Food and Water Safety Testing: Products ensuring the microbiological safety of consumables, essential for regulatory compliance in the food and beverage sector.
- Forensics: Technologies used in criminal investigations, including DNA profiling and analysis.
- Plant and Animal Genotyping: Solutions aiding in agricultural research and veterinary diagnostics, crucial for breeding programs and disease management.
Products and Services
Qiagen N.V. boasts an extensive portfolio that addresses various needs across the life science sector:
1. Sample and Assay Technologies:
Qiagen provides a comprehensive range of kits and reagents enabling the isolation, purification, and analysis of biomolecules (DNA, RNA, proteins) pivotal in various research and diagnostic applications.
2. Automated Instruments:
To enhance efficiency in sample processing, Qiagen offers advanced automation solutions, including:
- Liquid Handling Systems: Automating steps in sample preparation and assay workflows.
- Nucleic Acid Extraction Platforms: Devices designed to streamline extraction processes, significantly reducing manual handling.
3. Molecular Diagnostics Solutions:
Qiagen presents a robust suite of molecular diagnostic products, which include:
- Real-time PCR Assays: High-fidelity tests for detecting specific nucleic acids in biological samples.
- Hybridization Assays: Techniques designed for the detection of specific DNA or RNA sequences.
- Automation Systems: Integrated solutions that enhance laboratory efficiencies and reduce error rates in clinical testing environments.
4. Bioinformatics Software:
Qiagen develops software that aids in the analysis of genomic data, offering tools for:
- DNA and RNA Sequencing Analysis: Facilitating the interpretation of results from sequencing experiments.
- Pathway Analysis and Biological Network Software: Supporting researchers in understanding the biological implications of their findings.
5. Research Services:
Qiagen provides extensive research services aimed at:
- Genomic Analysis: Assisting clients in undertaking complex genomic studies.
- Biomarker Discovery: Supporting the identification of new biomarkers for diseases.
- Assay Development: Collaborating with pharmaceutical and biotech companies to develop and optimize diagnostic assays.
Conclusion
Qiagen N.V. is at the forefront of biotechnological advancements, empowering researchers, clinicians, and businesses across the life sciences spectrum. Its innovative products and services are instrumental in expediting scientific progress, enhancing personalized healthcare solutions, and ultimately improving patient outcomes and quality of life. The company's broad range of offerings ensures that it meets the diverse and evolving needs of its various customer segments in the life sciences industry.
Annual Report on Qiagen N v Divisions, Sales by Country |
| |
| Molecular Diagnostics |
|
 56.19 % |
of total Revenue |
| Life Sciences |
|
46.87 % |
of total Revenue |
| Consumables and related Molecular Diagnostics |
|
52.41 % |
of total Revenue |
| Consumables and related Life Sciences |
|
39.3 % |
of total Revenue |
| Instruments Molecular Diagnostics |
|
3.78 % |
of total Revenue |
| Instruments Life Sciences |
|
7.58 % |
of total Revenue |
| Sample technologies |
|
33.45 % |
of total Revenue |
| Diagnostic solutions |
|
39.02 % |
of total Revenue |
| PCR Nucleic acid amplification |
|
15.65 % |
of total Revenue |
| Genomics NGS |
|
12.17 % |
of total Revenue |
| Other |
|
2.77 % |
of total Revenue |
| Reportable Segment |
|
103.07 % |
of total Revenue |
| Netherlands |
|
1.09 % |
of total Revenue |
| Total Americas |
|
53.75 % |
of total Revenue |
| United States |
|
49.08 % |
of total Revenue |
| Other Americas |
|
4.67 % |
of total Revenue |
| Europe Middle East and Africa |
|
33.79 % |
of total Revenue |
| Asia Pacific Japan and Rest of World |
|
15.53 % |
of total Revenue |
Twelve months ended 2024
|
| QGEN s Annual Revenue by Geography and Business Segments |
Sales
(in millions $) |
%
(of total Sales) |
| Molecular Diagnostics |
1,078.57 |
56.19 % |
| Life Sciences |
899.65 |
46.87 % |
| Consumables and related Molecular Diagnostics |
1,005.98 |
52.41 % |
| Consumables and related Life Sciences |
754.26 |
39.3 % |
| Instruments Molecular Diagnostics |
72.58 |
3.78 % |
| Instruments Life Sciences |
145.39 |
7.58 % |
| Sample technologies |
642.03 |
33.45 % |
| Diagnostic solutions |
748.89 |
39.02 % |
| PCR Nucleic acid amplification |
300.47 |
15.65 % |
| Genomics NGS |
233.61 |
12.17 % |
| Other |
53.22 |
2.77 % |
| Reportable Segment |
1,978.21 |
103.07 % |
| Netherlands |
20.90 |
1.09 % |
| Total Americas |
1,031.57 |
53.75 % |
| United States |
942.01 |
49.08 % |
| Other Americas |
89.56 |
4.67 % |
| Europe Middle East and Africa |
648.49 |
33.79 % |
| Asia Pacific Japan and Rest of World |
298.15 |
15.53 % |
| Total |
1,919.35 |
100 % |
Twelve months ended 2024
|
| QGEN s Annual Income by Country and Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Reportable Segment |
967.35 |
48.9 % |
| Total |
83.59 |
4.36 % |
Twelve months ended 2024
|
| Annual Revenue and Income Growth by Country and Business Segments |
% Y/Y Sales Growth |
% Y/Y Income Growth |
| Molecular Diagnostics |
4.16 % |
- |
| Life Sciences |
-3.25 % |
- |
| Consumables and related Molecular Diagnostics |
5.74 % |
- |
| Consumables and related Life Sciences |
-2.66 % |
- |
| Instruments Molecular Diagnostics |
-13.71 % |
- |
| Instruments Life Sciences |
-6.19 % |
- |
| Sample technologies |
-3.16 % |
- |
| Diagnostic solutions |
7.35 % |
- |
| PCR Nucleic acid amplification |
0.09 % |
- |
| Genomics NGS |
-2.22 % |
- |
| Other |
-18.84 % |
- |
| Reportable Segment |
0.66 % |
-21.59 % |
| Netherlands |
2.96 % |
- |
| Total Americas |
1.13 % |
- |
| United States |
0.72 % |
- |
| Other Americas |
5.64 % |
- |
| Europe Middle East and Africa |
3.83 % |
- |
| Asia Pacific Japan and Rest of World |
-7.03 % |
- |
|
|
